Baidu
map

NEJM:万人对照试验显示ω-3脂肪酸补剂对糖尿病人预防心血管疾病发病和死亡没用

2018-08-30 奇点糕 奇点网

本篇论文同样发表在《新英格兰医学杂志》上,牛津大学的研究者们分析ASCEND数据发现,约1.5万糖尿病患者,在7.4年随访期间,每日服用1g Omega-3脂肪酸补剂与1g橄榄油的患者相比,在心血管疾病发病率及全因死亡率上,并没有表现出显着差异。

自从电商们从单身狗手里抢走了双十一,咱们兜里的钱就再也保不住了。不买新衣服、不买化妆品、不买小零食,健康你还不“买”点?护眼的、护肝的、护你小心脏的,现代人成天对着电脑吃外卖熬夜,感觉这些药片胶囊吃了能缓解好多猝死焦虑!

焦虑是缓解了,但真能让你少得病吗?起码深海鱼油应该不行!

周一谭老师给大家解读了欧洲心脏病学会年会(ESC 2018)上公布的ASCEND试验的结果,神药阿司匹林可能要“过气”了。因为这项试验是2×2交叉设计,同时评估阿司匹林和Omega-3脂肪酸补充剂对血管疾病的预防效果,那么就有读者问了,鱼油行吗?

本篇论文同样发表在《新英格兰医学杂志》上,牛津大学的研究者们分析ASCEND数据发现,约1.5万糖尿病患者,在7.4年随访期间,每日服用1g Omega-3脂肪酸补剂与1g橄榄油的患者相比,在血管疾病发病率及全因死亡率上,并没有表现出显着差异。

其实奇点糕之前也写过一项meta分析,从10项临床试验、近8万参与者数据来看,Omega-3脂肪酸补剂对预防心血管疾病恐怕是没啥用。在这些参与者中,三分之一以上是有糖尿病史的。

糖尿病确实是心血管疾病的高危因素之一,糖尿病患者的心血管疾病发病风险和死亡风险要比非患者高2-3倍[2]。对这部分人群来说,采取一定的措施预防就更加有必要了。

那么指南是怎么说的呢?

目前,美国心脏协会的指南建议可以补充Omega-3脂肪酸补剂用于冠心病的二级预防[3],并且在饮食中增加鱼类作为心血管疾病的一级预防[4]。

吃鱼确实有理论数据支持,不同的观察队列结果都显示,每周吃1-2次鱼与心脏病风险降低有关[5,6]。2002年,一项研究显示,每天摄入40-60g鱼(含有0.2-1g Omega-3脂肪酸)与心血管疾病死亡率降低约50%有关[7]。

可是具体落实到Omega-3脂肪酸上,结果就略有些尴尬了。

从2005年到2011年,共有15480名2型糖尿病患者入组,平均随访7.4年,其中脂肪酸组随访57022人年,安慰剂组随访56924人年。脂肪酸组患者每天服用1g的Omega-3脂肪酸补剂,其中含有460mgEPA和380mgDHA;安慰剂组则服用等量的橄榄油。


分组很随机,基线很一致~

研究者还特别随机抽出了152名患者,定期检查他们的血液样本,测量EPA和DHA的水平。安慰剂组患者的Omega-3脂肪酸水平几乎没变(6.6%vs6.5%);脂肪酸组患者则从7.1%增加到了9.1%,相对增加了32.5%,可见补剂没有白吃。

然而没白吃是一回事,有没有用又是另一回事。

研究的主要终点为首次严重血管事件,例如非致死心梗或中风、一过性脑缺血等。脂肪酸组中有689名患者(8.9%)、安慰剂组中有712名患者(9.2%)发生了严重血管事件,两组之间在统计学上没有差异!


p值0.55,惨

综合了血运重建对次要终点进行分析之后,脂肪酸组和安慰剂组更是毫无差别(11.4%vs11.5%)!


风险比直接1.0了……

再看看死亡率的数据,脂肪酸组和安慰剂组的全因死亡率分别为9.7%和10.2%,风险比只有0.95;这点差异倒是主要体现在血管事件上了,在癌症等其他原因造成的死亡上不很明显。


差异不太大

总的来说,这项临床试验结果与此前的研究还是很一致的——一致表示Omega-3脂肪酸补剂对于预防心血管疾病发生没啥用。

那咋的吃鱼有用吃Omega-3就没用呢?研究者也给出了自己的答案:毕竟鱼是一种食物,很难在实验设计中严格控制,它本身就含有很多的营养成分,而吃一样食物又会影响其他食物的摄入;目前对吃鱼的建议都是基于观察队列的,确实也没法说到底是什么起了作用。

预防心血管疾病,最有效的还是健康生活大法了!别太胖别太瘦,均衡饮食,适当运动,杜绝抽烟喝酒熬大夜,浪漫地一起健康变老吧~

原始出处:The ASCEND Study Collaborative Group. Effects of n?3 Fatty Acid Supplements in Diabetes Mellitus. NEJM. August 26, 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2019-06-03 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1779155, encodeId=ae971e79155c4, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Nov 03 12:07:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778779, encodeId=156c1e78779ae, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri Apr 12 21:07:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775420, encodeId=d6571e7542049, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 03 20:07:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987225, encodeId=dd1e198e225b7, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Wed Jul 10 00:07:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329888, encodeId=58db13298887d, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498468, encodeId=251614984688c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Sep 01 07:07:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041807, encodeId=0b80104180e6f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Aug 30 19:07:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

JAMA Cardiol:Meta分析:高危患者服用ω-3脂肪酸对心血管无益

近期,牛津大学学者在JAMA内科上发表的一项Meta分析表明,每日补充ω-3脂肪酸(FAS)并不能降低高危人群致命或非致命性冠心病或大血管事件的发生率。

盘点:不容小觑的ω-3脂肪酸

ω-3脂肪酸是机体的必须脂肪酸,可对机体产生多种健康益处。但是人体并不能合成ω-3脂肪酸,需要从食物中获得。ω-3脂肪酸共有11种类型,其中最重要的3种分别是ALA(α-亚麻酸)、EPA(二十碳五烯酸)和DHA(二十二碳六烯酸)。这里梅斯小编整理了近期关于ω-3脂肪酸的重要研究进展与大家一同分享。【1】Meta分析表明ω-3脂肪酸可降低心脏病、高脂血病风险一项由一个随机对照试验(RCT)的荟萃

J Hypertens:全血中的ω-3脂肪酸浓度与年轻健康成年人的血压呈负相关!

由此可见,较高的Omega-3指数与血压正常的年轻人和健康人SBP和DBP水平降低之间具有显著相关性。富含n-3 FA的饮食可能是高血压一级预防的策略。

Stroke:ω-3脂肪酸和缺血性卒中之间的相关性分析!

由此可见,循环中高水平DHA与动脉粥样硬化性脑卒中以及DPA与心源性脑卒中的发生呈负相关。这些新的发现表明DHA、DPA和二十碳五烯酸产生有益效应的作用途径不一样。

Am J Clin Nutr:孕期血浆ω-3脂肪酸含量预示了产后是否肥胖?

2017年5月,发表在《Am J Clin Nutr》的一项基于亚洲女性的队列研究,得出了孕妇血浆ω-3脂肪酸与产后体重保留负相关的结论。

J Clin Lipidol:ω-3脂肪酸可以降低死亡和心血管疾病风险吗?

ω-3脂肪酸水平与任何原因的死亡风险和心血管疾病(CVD)发病风险相关到何种程度仍然有争议。2018年5月,发表在《J Clin Lipidol》的一项前瞻性和观察性研究调查了红细胞长链ω-3脂肪酸水平与死亡率和心血管疾病发病风险的相关性。

Baidu
map
Baidu
map
Baidu
map